$DRNA on NASDAQ
December 28, 2021
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
December 25, 2021
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
November 18, 2021
Novo Nordisk to Acquire Dicerna
November 12, 2021
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
November 12, 2021
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
November 09, 2021
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 04, 2021
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
November 02, 2021
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
October 19, 2021
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
October 15, 2021
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
October 14, 2021
Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November
October 01, 2021
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2021
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
September 22, 2021
Dicerna Announces New Executive Leadership Appointments
September 02, 2021
Dicerna to Participate in 16th Annual Citi Biopharma Conference
August 09, 2021
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
August 05, 2021
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
August 02, 2021
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
July 29, 2021
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
July 21, 2021
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
July 01, 2021
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2021
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
June 16, 2021
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
June 03, 2021
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
May 27, 2021
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
May 24, 2021
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
May 12, 2021
Dicerna to Participate in Upcoming Investor Conferences
May 06, 2021
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
April 29, 2021
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
April 08, 2021
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
April 01, 2021
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2021
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
March 24, 2021
Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress
March 11, 2021
Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021
March 04, 2021
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
February 25, 2021
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
February 18, 2021
Dicerna to Participate in Upcoming Investor Conferences
February 18, 2021
Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021
February 11, 2021
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
January 05, 2021
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
January 05, 2021
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
January 04, 2021
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2021
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
December 01, 2020
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2020
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
November 16, 2020
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
November 11, 2020
Dicerna to Participate in Upcoming Investor Conferences
November 10, 2020
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
November 05, 2020
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
November 02, 2020
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- No Recent Filings Found.
